KR101990936B1 - 항바이러스 화합물 - Google Patents
항바이러스 화합물 Download PDFInfo
- Publication number
- KR101990936B1 KR101990936B1 KR1020187004491A KR20187004491A KR101990936B1 KR 101990936 B1 KR101990936 B1 KR 101990936B1 KR 1020187004491 A KR1020187004491 A KR 1020187004491A KR 20187004491 A KR20187004491 A KR 20187004491A KR 101990936 B1 KR101990936 B1 KR 101990936B1
- Authority
- KR
- South Korea
- Prior art keywords
- optionally substituted
- independently
- alkyl
- carbocycle
- halogen
- Prior art date
Links
- 0 C**CCC(C)*(*CC**N)C(C1CC1)O Chemical compound C**CCC(C)*(*CC**N)C(C1CC1)O 0.000 description 59
- MVHOAOSHABGEFL-UHFFFAOYSA-N Cc1nc(cc(C)cc2)c2[nH]1 Chemical compound Cc1nc(cc(C)cc2)c2[nH]1 MVHOAOSHABGEFL-UHFFFAOYSA-N 0.000 description 7
- NQHAZVXYSRRVLX-UHFFFAOYSA-N Cc(c(N)c(c(I)c1N)N)c1N Chemical compound Cc(c(N)c(c(I)c1N)N)c1N NQHAZVXYSRRVLX-UHFFFAOYSA-N 0.000 description 3
- SNBKIYGGKKMWGW-UHFFFAOYSA-N CC1N(C)CSC1 Chemical compound CC1N(C)CSC1 SNBKIYGGKKMWGW-UHFFFAOYSA-N 0.000 description 2
- XGNXYCFREOZBOL-UHFFFAOYSA-N Nc(cc1)cc2c1OCO2 Chemical compound Nc(cc1)cc2c1OCO2 XGNXYCFREOZBOL-UHFFFAOYSA-N 0.000 description 2
- JEKJRURDRGQQLY-UHFFFAOYSA-N BC1(C)CC2NC(C)=NC2CC1 Chemical compound BC1(C)CC2NC(C)=NC2CC1 JEKJRURDRGQQLY-UHFFFAOYSA-N 0.000 description 1
- ZHQIJGGKCQBNNB-UHFFFAOYSA-N C(C1)C1c1nc2ccccc2[s]1 Chemical compound C(C1)C1c1nc2ccccc2[s]1 ZHQIJGGKCQBNNB-UHFFFAOYSA-N 0.000 description 1
- BYHBHCVJNYRSEB-TXQJLUMCSA-N C(C1)CNC1c1nc2ccc([C@@H](CC[C@@H]3c4ccc5nc(C6NCCC6)[nH]c5c4)N3c3ccccc3)cc2[nH]1 Chemical compound C(C1)CNC1c1nc2ccc([C@@H](CC[C@@H]3c4ccc5nc(C6NCCC6)[nH]c5c4)N3c3ccccc3)cc2[nH]1 BYHBHCVJNYRSEB-TXQJLUMCSA-N 0.000 description 1
- SHUPZTODQWEVMR-UHFFFAOYSA-N CC(C(C1)C1C1)N1SC Chemical compound CC(C(C1)C1C1)N1SC SHUPZTODQWEVMR-UHFFFAOYSA-N 0.000 description 1
- JJFPOXGLDCWEDU-XEOVLGQKSA-N CC(C)(C)OC(N(CCC1)[C@@H]1C(Nc(ccc([C@@H](CC[C@@H]1c(cc2)cc(N)c2NC([C@H](CCC2)N2C(OC(C)(C)C)=O)=O)N1c(cc1)ccc1N(CC1)CCC1c1ccccc1)c1)c1N)=O)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@@H]1C(Nc(ccc([C@@H](CC[C@@H]1c(cc2)cc(N)c2NC([C@H](CCC2)N2C(OC(C)(C)C)=O)=O)N1c(cc1)ccc1N(CC1)CCC1c1ccccc1)c1)c1N)=O)=O JJFPOXGLDCWEDU-XEOVLGQKSA-N 0.000 description 1
- VMFSOQWTEGFFDM-IRJAKFTQSA-N CC(C)(C)OC(N(CCC1)[C@@H]1C(Nc(ccc([C@@H](CC[C@@H]1c(cc2[N+]([O-])=O)ccc2NC([C@H](CCC2)N2C(OC(C)(C)C)=O)=O)N1c(cc1)ccc1N(CC1)CCC1c1ccccc1)c1)c1[N+]([O-])=O)=O)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@@H]1C(Nc(ccc([C@@H](CC[C@@H]1c(cc2[N+]([O-])=O)ccc2NC([C@H](CCC2)N2C(OC(C)(C)C)=O)=O)N1c(cc1)ccc1N(CC1)CCC1c1ccccc1)c1)c1[N+]([O-])=O)=O)=O VMFSOQWTEGFFDM-IRJAKFTQSA-N 0.000 description 1
- NXEGYGPYSYLFSB-BSOSBYQFSA-N CC(C)(C)OC(N([C@@H](CCC1)C1C1)[C@@H]1C(OCc1ccccc1)=O)=O Chemical compound CC(C)(C)OC(N([C@@H](CCC1)C1C1)[C@@H]1C(OCc1ccccc1)=O)=O NXEGYGPYSYLFSB-BSOSBYQFSA-N 0.000 description 1
- HOCJGVCEHVCLNT-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1N(C1)CC1(c1cc(B2OC(C)(C)C(C)(C)O2)ccc1)c1cccc(B2OC(C)(C)C(C)(C)O2)c1 Chemical compound CC(C)(C)c(cc1)ccc1N(C1)CC1(c1cc(B2OC(C)(C)C(C)(C)O2)ccc1)c1cccc(B2OC(C)(C)C(C)(C)O2)c1 HOCJGVCEHVCLNT-UHFFFAOYSA-N 0.000 description 1
- QRUWCPBEXUJQPR-UHFFFAOYSA-N CC(C)(CC(N(C)C)=O)OC Chemical compound CC(C)(CC(N(C)C)=O)OC QRUWCPBEXUJQPR-UHFFFAOYSA-N 0.000 description 1
- OGCSWBYAHCJRNV-OHPVVHOMSA-N CC(C)[C@@H](C(N(CCC1)C1c1ncc(-c2ccc(C3(C)C=CC(c4cnc([C@H](CCC5)N5C(C(C(C)C)NC(OC)=O)=O)[nH]4)=CC3)cc2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)C1c1ncc(-c2ccc(C3(C)C=CC(c4cnc([C@H](CCC5)N5C(C(C(C)C)NC(OC)=O)=O)[nH]4)=CC3)cc2)[nH]1)=O)NC(OC)=O OGCSWBYAHCJRNV-OHPVVHOMSA-N 0.000 description 1
- MMWDYHCSBBTKRZ-YPHAAILGSA-N CC(C)[C@@H](C(N(C[C@@H](C1)OC)C1C(C)C)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)OC)C1C(C)C)=O)NC(OC)=O MMWDYHCSBBTKRZ-YPHAAILGSA-N 0.000 description 1
- XGNMBMRAWATDEU-VIFPVBQESA-N CC(C)[C@H](CCC1)N1C(CNC(OC)=O)=O Chemical compound CC(C)[C@H](CCC1)N1C(CNC(OC)=O)=O XGNMBMRAWATDEU-VIFPVBQESA-N 0.000 description 1
- VRIQYBZGKWZHEL-KBPBESRZSA-N CC(C)[C@H](CCC1)N1C([C@H](C1CCOCC1)NC(OC)=O)=O Chemical compound CC(C)[C@H](CCC1)N1C([C@H](C1CCOCC1)NC(OC)=O)=O VRIQYBZGKWZHEL-KBPBESRZSA-N 0.000 description 1
- GULDWPYHMVXFJW-WOPDTQHZSA-N CC(C)[C@H](CCC1)N1C([C@H]([C@@H](C)OC)NC(OC)=O)=O Chemical compound CC(C)[C@H](CCC1)N1C([C@H]([C@@H](C)OC)NC(OC)=O)=O GULDWPYHMVXFJW-WOPDTQHZSA-N 0.000 description 1
- XPQDAIPCBCVWIJ-UHFFFAOYSA-N CC(C)c1cc(CCC2)c2cc1 Chemical compound CC(C)c1cc(CCC2)c2cc1 XPQDAIPCBCVWIJ-UHFFFAOYSA-N 0.000 description 1
- VHPYYCVUVBNTEA-UHFFFAOYSA-N CC(C=C)=[N]=CC=C Chemical compound CC(C=C)=[N]=CC=C VHPYYCVUVBNTEA-UHFFFAOYSA-N 0.000 description 1
- MKPZDBNKUJHYCK-UHFFFAOYSA-N CC1N(C)CC1 Chemical compound CC1N(C)CC1 MKPZDBNKUJHYCK-UHFFFAOYSA-N 0.000 description 1
- MWUISCCBFHLWLY-UHFFFAOYSA-N CC1N(C)CCCC1 Chemical compound CC1N(C)CCCC1 MWUISCCBFHLWLY-UHFFFAOYSA-N 0.000 description 1
- MRVKZWJOSLLFML-UHFFFAOYSA-N CCCN1C(C)CCCC1 Chemical compound CCCN1C(C)CCCC1 MRVKZWJOSLLFML-UHFFFAOYSA-N 0.000 description 1
- BPDKBUDXSHJZKO-MNOVXSKESA-N CC[C@H](CCC1)N1C([C@H](C(C)C)NC(OC)=O)=O Chemical compound CC[C@H](CCC1)N1C([C@H](C(C)C)NC(OC)=O)=O BPDKBUDXSHJZKO-MNOVXSKESA-N 0.000 description 1
- NYXHSRNBKJIQQG-UHFFFAOYSA-N CNC(OC)=O Chemical compound CNC(OC)=O NYXHSRNBKJIQQG-UHFFFAOYSA-N 0.000 description 1
- HLZYXJLJCKAYJM-QZTJIDSGSA-N CS(O[C@H](CC[C@H](c(cc1)ccc1[N+]([O-])=O)OS(C)(=O)=O)c(cc1)ccc1[N+]([O-])=O)(=O)=O Chemical compound CS(O[C@H](CC[C@H](c(cc1)ccc1[N+]([O-])=O)OS(C)(=O)=O)c(cc1)ccc1[N+]([O-])=O)(=O)=O HLZYXJLJCKAYJM-QZTJIDSGSA-N 0.000 description 1
- MUFNEHJGJZWXTJ-UUEFVBAFSA-N C[C@@H](C(C(CNC)=O)NC(OC)=O)OC Chemical compound C[C@@H](C(C(CNC)=O)NC(OC)=O)OC MUFNEHJGJZWXTJ-UUEFVBAFSA-N 0.000 description 1
- YZWRZWGXUYUVDD-NXEZZACHSA-N C[C@H](CCC1)N1C([C@H](C(C)(C)C)NC(OC)=O)=O Chemical compound C[C@H](CCC1)N1C([C@H](C(C)(C)C)NC(OC)=O)=O YZWRZWGXUYUVDD-NXEZZACHSA-N 0.000 description 1
- CBJIAFLWRZQQQF-SCZZXKLOSA-N C[C@H](CCC1)N1C([C@H](C1CC1)NC(OC)=O)=O Chemical compound C[C@H](CCC1)N1C([C@H](C1CC1)NC(OC)=O)=O CBJIAFLWRZQQQF-SCZZXKLOSA-N 0.000 description 1
- JGWSVSORQOSXPT-DCOKYQHHSA-N C[C@H]([C@@](C)(C(N1C(CCC2)C2CC1C)=O)NC(OC)=O)OC Chemical compound C[C@H]([C@@](C)(C(N1C(CCC2)C2CC1C)=O)NC(OC)=O)OC JGWSVSORQOSXPT-DCOKYQHHSA-N 0.000 description 1
- XUIQKDLUKYNIJF-UHFFFAOYSA-N Cc([nH]c1c2)nc1cc(C)c2F Chemical compound Cc([nH]c1c2)nc1cc(C)c2F XUIQKDLUKYNIJF-UHFFFAOYSA-N 0.000 description 1
- LLPKQRMDOFYSGZ-UHFFFAOYSA-N Cc1cnc(C)[nH]1 Chemical compound Cc1cnc(C)[nH]1 LLPKQRMDOFYSGZ-UHFFFAOYSA-N 0.000 description 1
- CBZCPOLNFVBFHQ-UHFFFAOYSA-N NCC(C1NCCC1)=O Chemical compound NCC(C1NCCC1)=O CBZCPOLNFVBFHQ-UHFFFAOYSA-N 0.000 description 1
- SMWAOXCEPHEGFV-UHFFFAOYSA-N Nc1nc(CCCC2)c2[s]1 Chemical compound Nc1nc(CCCC2)c2[s]1 SMWAOXCEPHEGFV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/903,822 US20110092415A1 (en) | 2009-06-11 | 2010-10-13 | Anti-Viral Compounds |
US12/903,822 | 2010-10-13 | ||
US12/964,027 | 2010-12-09 | ||
US12/964,027 US8921514B2 (en) | 2009-06-11 | 2010-12-09 | Anti-viral compounds |
US201161446800P | 2011-02-25 | 2011-02-25 | |
US61/446,800 | 2011-02-25 | ||
US13/100,827 | 2011-05-04 | ||
US13/100,827 US8937150B2 (en) | 2009-06-11 | 2011-05-04 | Anti-viral compounds |
PCT/US2011/056045 WO2012051361A1 (en) | 2010-10-13 | 2011-10-12 | Anti-viral compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020147025969A Division KR101831154B1 (ko) | 2010-10-13 | 2011-10-12 | 항바이러스 화합물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180026775A KR20180026775A (ko) | 2018-03-13 |
KR101990936B1 true KR101990936B1 (ko) | 2019-06-19 |
Family
ID=55069204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020187004491A KR101990936B1 (ko) | 2010-10-13 | 2011-10-12 | 항바이러스 화합물 |
Country Status (19)
Country | Link |
---|---|
JP (4) | JP2016106075A (sl) |
KR (1) | KR101990936B1 (sl) |
CA (1) | CA2938547A1 (sl) |
CY (1) | CY1117188T1 (sl) |
DK (1) | DK2692346T3 (sl) |
ES (1) | ES2560842T3 (sl) |
GT (1) | GT201300093AA (sl) |
HK (1) | HK1188717A1 (sl) |
HR (1) | HRP20151389T1 (sl) |
HU (1) | HUE026832T2 (sl) |
IL (2) | IL225010A (sl) |
ME (1) | ME02328B (sl) |
MY (1) | MY164064A (sl) |
PT (1) | PT2692346E (sl) |
RS (1) | RS54619B1 (sl) |
SI (1) | SI2692346T1 (sl) |
TW (1) | TWI621611B (sl) |
UA (1) | UA113048C2 (sl) |
ZA (3) | ZA201302269B (sl) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201706806D0 (en) | 2017-04-28 | 2017-06-14 | Sentinel Oncology Ltd | Pharmaceutical compounds |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008144380A1 (en) | 2007-05-17 | 2008-11-27 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9206623A (pt) * | 1991-10-11 | 1995-05-02 | Du Pont Merck Pharma | Uréias cíclicas e análogas úteis como inibidoras da protease retroviral |
US5840721A (en) * | 1997-07-09 | 1998-11-24 | Ontogen Corporation | Imidazole derivatives as MDR modulators |
US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
NZ593806A (en) * | 2008-12-03 | 2014-04-30 | Presidio Pharmaceuticals Inc | Inhibitors of hcv ns5a |
US9394279B2 (en) * | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
JP5530514B2 (ja) * | 2009-06-11 | 2014-06-25 | アッヴィ・バハマズ・リミテッド | Hcv感染を治療するための抗ウィルス化合物 |
US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
-
2011
- 2011-10-12 ME MEP-2016-14A patent/ME02328B/me unknown
- 2011-10-12 RS RS20160128A patent/RS54619B1/en unknown
- 2011-10-12 PT PT131910416T patent/PT2692346E/pt unknown
- 2011-10-12 CA CA2938547A patent/CA2938547A1/en not_active Abandoned
- 2011-10-12 HU HUE13191041A patent/HUE026832T2/en unknown
- 2011-10-12 SI SI201130697T patent/SI2692346T1/sl unknown
- 2011-10-12 KR KR1020187004491A patent/KR101990936B1/ko active IP Right Grant
- 2011-10-12 MY MYPI2013700273A patent/MY164064A/en unknown
- 2011-10-12 TW TW102143104A patent/TWI621611B/zh active
- 2011-10-12 DK DK13191041.6T patent/DK2692346T3/en active
- 2011-10-12 ES ES13191041.6T patent/ES2560842T3/es active Active
- 2011-12-10 UA UAA201305877A patent/UA113048C2/uk unknown
-
2013
- 2013-02-28 IL IL225010A patent/IL225010A/en active IP Right Grant
- 2013-03-26 ZA ZA2013/02269A patent/ZA201302269B/en unknown
-
2014
- 2014-01-13 GT GT201300093AK patent/GT201300093AA/es unknown
- 2014-02-25 HK HK14101772.6A patent/HK1188717A1/zh unknown
-
2015
- 2015-10-29 JP JP2015212539A patent/JP2016106075A/ja active Pending
- 2015-12-17 HR HRP20151389TT patent/HRP20151389T1/hr unknown
-
2016
- 2016-02-12 CY CY20161100115T patent/CY1117188T1/el unknown
-
2017
- 2017-08-15 ZA ZA2017/05519A patent/ZA201705519B/en unknown
- 2017-11-22 JP JP2017224527A patent/JP6586147B2/ja active Active
-
2018
- 2018-08-16 IL IL261206A patent/IL261206B/en active IP Right Grant
-
2019
- 2019-05-24 ZA ZA2019/03284A patent/ZA201903284B/en unknown
- 2019-09-05 JP JP2019161909A patent/JP6790202B2/ja active Active
-
2020
- 2020-11-02 JP JP2020183474A patent/JP2021035964A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008144380A1 (en) | 2007-05-17 | 2008-11-27 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
Also Published As
Publication number | Publication date |
---|---|
PT2692346E (pt) | 2016-03-22 |
JP2016106075A (ja) | 2016-06-16 |
HRP20151389T1 (hr) | 2016-01-15 |
SI2692346T1 (sl) | 2016-03-31 |
JP6586147B2 (ja) | 2019-10-02 |
DK2692346T3 (en) | 2016-02-29 |
ME02328B (me) | 2016-06-20 |
MY164064A (en) | 2017-11-15 |
UA113048C2 (xx) | 2016-12-12 |
HUE026832T2 (en) | 2016-07-28 |
RS54619B1 (en) | 2016-08-31 |
IL261206B (en) | 2019-12-31 |
TW201412707A (zh) | 2014-04-01 |
HK1188717A1 (zh) | 2014-05-16 |
ZA201705519B (en) | 2019-04-24 |
JP2020059696A (ja) | 2020-04-16 |
JP2018065828A (ja) | 2018-04-26 |
CY1117188T1 (el) | 2017-04-05 |
KR20180026775A (ko) | 2018-03-13 |
ZA201302269B (en) | 2021-05-26 |
JP6790202B2 (ja) | 2020-11-25 |
CA2938547A1 (en) | 2012-04-19 |
IL225010A (en) | 2016-04-21 |
JP2021035964A (ja) | 2021-03-04 |
IL261206A (en) | 2018-10-31 |
ES2560842T3 (es) | 2016-02-23 |
GT201300093AA (es) | 2015-07-08 |
ZA201903284B (en) | 2021-01-27 |
TWI621611B (zh) | 2018-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101831154B1 (ko) | 항바이러스 화합물 | |
US20110092415A1 (en) | Anti-Viral Compounds | |
US20120220562A1 (en) | Anti-Viral Compounds | |
JP6790202B2 (ja) | 抗ウィルス化合物 | |
AU2016238925B2 (en) | Anti-viral compounds | |
AU2014203655B2 (en) | Anti-viral compounds | |
US20230285378A1 (en) | Anti-Viral Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |